A multimodal regimen combining targeted oral inhibitors with intrathecal chemotherapy achieved complete remission and prolonged functional recovery in a rare ...
A retrospective single-center study of 75 treatment-naive CLL/SLL patients reports an 86.7% response rate with frontline orelabrutinib monotherapy and no ...
A propensity-matched analysis of nearly 20,000 patients reveals that aggressive diffuse large B-cell lymphoma carries a higher risk of acute ...
A nationwide cohort of 410 patients shows zanubrutinib delivers high progression-free survival in CLL/SLL, with dose reductions and switches between ...
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!
